Table 1.

Effects of selective 5-HT receptor ligands alone or in combination with an SSRI on immobility in the tail suspension test or forced swimming test in mice

Class of 5-HT receptor	Compound	Alone	Plus SSRI
5-HT1A/B agonist
	RU24969a,b	↓	↓
5-HT1A agonists
	8-OH-DPATc,d,e	↓
	LB50016f	↓
	MKC-242g	↓
5-HT1A antagonists
	WAY-100635a,d,h	⇆	↑d,h; ⇆a
	NAN190e	⇆
5-HT1B agonists
	Anpirtolineb,i	↓
	GP94253j	↓
5-HT1B antagonist
	GR125743a,h,k	⇆	↑a,k; ↓h
5-HT2A/C agonist
	DOIl	⇆
5-HT2A/C antagonists
	LY53857d		↑
	Ritanserinl	↓
5-HT2A antagonist/SSRI
	YM992m		↓
5-HT2C agonists
	WAY 161503n	↓
	RO 60-0175n	↓
	RO 60-0332n	↓
5-HT2C antagonist
	SB206553n,o	⇆	↓o; ↑n
5-HT3 antagonists
	Ondansetronl	↓
	MDL72222p	↓
5-HT4 antagonist
	SB 204070Aq	⇆	⇆
5-HT6 agonist
	EMDT	↓
5-HT6 antagonist
	SB271046		↑
5-HT7 antagonists
	SB-258719r	↓
	SB-269970s	↓

↓, Decreased immobility; ↑, increased/potentiated immobility; ⇆, no effect on immobility. References:

^aO'Neill et al., 1996;

^bRedrobe and Bourin, 1999;

^cBiala, 1998;

^dMiyata et al., 2004;

^eRedrobe et al., 1996;

^fLee et al., 1999;

^gMatsuda et al., 1995;

^hMayorga et al., 2001;

ⁱO'Neill and Conway, 2001;

^jTatarczynska et al., 2005;

^kGardier et al., 2001;

^lRedobe and Bourin, 1997;

^mTakeuchi et al., 1997;

ⁿCryan and Lucki, 2000b;

^oCremers et al., 2004;

^pKos et al., 2006;

^qCryan and Lucki, 2000a;

^rGuscott et al., 2005;

^sHedlund et al., 2005.

^{n, q} Studies were performed on rats.